Ashkan Shoamanesh: OCEANIC-STROKE Focus on Stroke Subtypes and Response to Asundexian at ISC26
Ashkan Shoamanesh, Associate Professor of Medicine (Neurology), Marta and Owen Boris Chair in Stroke Research and Care at McMaster University, shared on LinkedIn:
”It was a pleasure to discuss the results of our secondary analyses of the OCEANIC-STROKE trial focused on qualifying ischemic stroke subtype and response to asundexian with Video Journal of Neurology (VJNeurology) at ISC26.
Our results demonstrate consistency in the treatment effect of asundexian irrespective of underlying etiology, including robust reductions in ischemic stroke in patients with qualifying stroke due to small vessel occlusive disease (HR 0.61, 95%CI 0.46-0.81) and embolic stroke of undetermined source (HR 0.53, 95%CI 0.37-0.78), without excess in major bleeding or intracranial hemorrhage!
Eagerly awaiting approval of asundexian for the betterment of stroke prevention in our patients with non-cardioembolic ischemic stroke or high-risk TIA.”
Stay updated with Hemostasis Today.
-
Oct 7, 2026, 16:44Amor Salah: 2026 NCS/SCCM Guidelines for Managing Antithrombotic-Associated ICH
-
Oct 7, 2026, 16:04NETs in Thrombosis: From Mechanism to Therapeutic Target
-
Oct 7, 2026, 15:28Amir Samimi: Prognostic Value of Platelet Count in Resected HNSCC
-
Oct 7, 2026, 15:21Eloïse Laouenan: Bridging Immunity and Thrombosis in MVTE
-
Oct 7, 2026, 15:10Uthra Sundaram: Honouring Donors During International Plasma Awareness Week
-
Oct 7, 2026, 15:04Daniel Victor Ortigoza: Should Frail Older Patients With AF Switch From VKA to DOACs?
-
Oct 7, 2026, 14:53Susan Noone: Donor Turned Recipient Shares Lifesaving Transfusion Story
-
Oct 7, 2026, 14:49Aimee Burtenshaw: The Impact of the Infected Blood Inquiry on Hospital Transfusion Laboratories
-
Oct 7, 2026, 14:41Vikash Jaiswal: Does Timing Matter for Calcium in Pre-Eclampsia Prevention?